Hypoxia is a fundamental microenvironmental component of osteosarcoma which induces activation of the hypoxia-inducible factor-1 (HIF-1) pathway. Overexpression of HIF-1α has been linked to tumor resistance to radio- or chemotherapy. However, little is known about the effects of HIF-1α inhibition on hypoxic radioresistance of human osteosarcoma cells. Here, we investigated the effects of HIF-1α inhibition on cell survival and radiosensitivity in the MG-63 human osteosarcoma cell line.
Methods
HIF-1α inhibition was achieved by small interfering RNA (siRNA) targeting of HIF-1α or via chetomin. Inhibition of the HIF-1 pathway was determined by monitoring the expression levels of HIF-1α, carbonic anhydrase 9 (CA9) and vascular endothelial growth factor (VEGF) using quantitative real-time PCR and Western blot analyses. Clonogenic assay was performed after irradiation (2-10 Gy) to investigate the effect of HIF-1α inhibition on the radiosensitivity of human osteosarcoma cells under normoxic and hypoxic conditions.
Results
Compared to the control groups, treatment with HIF-1α siRNA or chetomin significantly reduced the hypoxia-inducible radioresistance of MG-63 cells. However, siRNA and chetomin showed different effects on the radiosensitivity under normoxic conditions.
Conclusions
Our results indicate that inhibition of HIF-1α effectively decreases hypoxia-induced transcription and radiosensitizes hypoxic MG-63 human osteosarcoma cells in vitro.
LuetkeA., MeyersP.A., LewisI., JuergensH.Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev.2014; 40(4): 523–532.
2.
SchwarzR., BrulandO., CassoniA., SchombergP., BielackS.The role of radiotherapy in oseosarcoma. Cancer Treat Res.2009; 152: 147–164.
3.
DeLaneyT.F., ParkL., GoldbergS.I.Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys.2005; 61(2): 492–498.
4.
OertelS., BlattmannC., RiekenS.Radiotherapy in the treatment of primary osteosarcoma—a single center experience. Tumori.2010; 96(4): 582–588.
5.
BertoutJ.A., PatelS.A., SimonM.C.The impact of O2 availability on human cancer. Nat Rev Cancer.2008; 8(12): 967–975.
6.
VaupelP., ThewsO., HoeckelM.Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol.2001; 18(4): 243–259.
7.
RichardD.E., BerraE., PouysségurJ.Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun.1999; 266(3): 718–722.
8.
MajmundarA.J., WongW.J., SimonM.C.Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell.2010; 40(2): 294–309.
9.
ZhongH., De MarzoA.M., LaughnerE.Overexpression of hypoxia-inducible factor-1alpha in common human cancers and their metastases. Cancer Res.1999; 59(22): 5830–5835.
10.
ChauN.M., RogersP., AherneW.Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Res.2005; 65(11): 4918–4928.
11.
YangQ.C., ZengB.F., DongY., ShiZ.M., JiangZ.M., HuangJ.Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn J Clin Oncol.2007; 37(2): 127–134.
12.
MizobuchiH., García-CastellanoJ.M., PhilipS., HealeyJ.H., GorlickR.Hypoxia markers in human osteosarcoma: an exploratory study. Clin Orthop Relat Res.2008; 466(9): 2052–2059.
13.
ChenW.L., FengH.J., LiH.G.Expression and significance of hypoxemia-inducible factor-1alpha in osteosarcoma of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.2008; 106(2): 254–257.
14.
RoncuzziL., PancottiF., BaldiniN.Involvement of HIF-1α activation in the doxorubicin resistance of human osteosarcoma cells. Oncol Rep.2014; 32(1): 389–394.
15.
HaradaH.How can we overcome tumor hypoxia in radiation therapy?J Radiat Res (Tokyo).2011; 52(5): 545–556.
16.
MeijerT.W., KaandersJ.H., SpanP.N., BussinkJ.Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res.2012; 18(20): 5585–5594.
17.
LiangD., YangM., GuoB., YangL., CaoJ., ZhangX.HIF-1α induced by β-elemene protects human osteosarcoma cells from undergoing apoptosis. J Cancer Res Clin Oncol.2012; 138(11): 1865–1877.
18.
WuQ., YangS.H., YeS.N., WangR.Y.Therapeutic effects of RNA interference targeting HIF-1 alpha gene on human osteosarcoma. Zhonghua Yi Xue Za Zhi.2005; 85(6): 409–413.
19.
KungA.L., ZabludoffS.D., FranceD.S.Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell.2004; 6(1): 33–43.
20.
StaabA., LoefflerJ., SaidH.M.Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer.2007; 7(1): 213.
21.
AdamskiJ., PriceA., DiveC., MakinG.Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha. PLoS ONE.2013; 8(6): e65304.
22.
GuoQ., GuoP., MaoQ.ID1 affects the efficacy of radiotherapy in glioblastoma through inhibition of DNA repair pathways. Med Oncol.2013; 30(1): 325.
23.
SemenzaG.L.Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci.2012; 33(4): 207–214.
24.
SadriN., ZhangP.J.Hypoxia-inducible factors: mediators of cancer progression; prognostic and therapeutic targets in soft tissue sarcomas. Cancers (Basel).2013; 5(2): 320–333.
El NaggarA., ClarksonP., ZhangF., MathersJ., TognonC., SorensenP.H.Expression and stability of hypoxia inducible factor 1α in osteosarcoma. Pediatr Blood Cancer.2012; 59(7): 1215–1222.
27.
VordermarkD., KafferA., RiedlS., KatzerA., FlentjeM.Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. Int J Radiat Oncol Biol Phys.2005; 61(4): 1197–1207.
28.
KoukourakisM.I., GiatromanolakiA., DanielidisV., SivridisE.Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy. Int J Radiat Biol.2008; 84(1): 47–52.
29.
HsiehC.H., LeeC.H., LiangJ.A., YuC.Y., ShyuW.C.Cycling hypoxia increases U87 glioma cell radioresistance via ROS induced higher and long-term HIF-1 signal transduction activity. Oncol Rep.2010; 24(6): 1629–1636.
30.
MizukamiY., KohgoY., ChungD.C.Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res.2007; 13(19): 5670–5674.
31.
TakenagaK.Angiogenic signaling aberrantly induced by tumor hypoxia. Front Biosci (Landmark Ed).2011; 16(1): 31–48.
32.
ForsytheJ.A., JiangB.H., IyerN.V.Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol.1996; 16(9): 4604–4613.
33.
KnowlesH.J., SchaeferK.L., DirksenU., AthanasouN.A.Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor. BMC Cancer.2010; 10(1): 372.
34.
Klotzsche-von AmelnA., MuschterA., MamloukS.Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFβ. Cancer Res.2011; 71(9): 3306–3316.
35.
KesslerJ., HahnelA., WichmannH.HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer.2010; 10(1): 605.
